Inicio › Enfermedad de obstrucción pulmonar crónica › South Carolina
Ensayos clínicos de Enfermedad de obstrucción pulmonar crónica en South Carolina
17 estudios sobre Enfermedad de obstrucción pulmonar crónica buscan participantes en South Carolina.
Ciudades en South Carolina
Texto oficial del estudio (inglés)
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
- Copd01 50020, North Charleston
- Copd01 50004, Rock Hill
- Copd01 50009, Spartanburg
- y 1 más
ReclutandoFase 2
Edades de 40 a 80 · Todos los sexos · Actualizado el 6 nov 2026 · NCT07725939Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)
- Lowcountry Lung & Critical Care, PA ( Site 4413), Charleston
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 6 nov 2026 · NCT07874815A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease
- PanAmerican Clinical Research, Bluffton
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 nov 2026 · NCT07908381To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
- Clinical Research of Rock Hill, Rock Hill
ReclutandoFase 2
Edades de 40 a 85 · Todos los sexos · Actualizado el 28 oct 2026 · NCT07684820A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
- GC2501 Study Site 101, Charleston
ReclutandoFase 3
Edades de 18 a 80 · Todos los sexos · Actualizado el 26 oct 2026 · NCT07555483A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Research Site, Lancaster
- Research Site, Spartanburg
ReclutandoFase 2
Edades de 40 en adelante · Todos los sexos · Actualizado el 23 oct 2026 · NCT07082738Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- MedTrial- Site Number : 8400010, Columbia
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 23 oct 2026 · NCT07190222A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Bogan Sleep Consultants, LLC, Columbia
- Velocity Clinical Research, Gaffney, Gaffney
- Clinical Research of Rock Hill, Rock Hill
- y 1 más
ReclutandoFase 2/3
Edades de 35 a 80 · Todos los sexos · Actualizado el 22 oct 2026 · NCT07363694Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- AnMed Oglesby Center- Site Number : 8400074, Anderson
- MD First Research - Lancaster- Site Number : 8400102, Lancaster
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 19 oct 2026 · NCT07190209STRIVE Post-Market Registry Study
- AnMed Health, Anderson
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 oct 2026 · NCT04302272A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- Research Site, Anderson
- Research Site, Columbia
- Research Site, Gaffney
- y 2 más
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 9 oct 2026 · NCT06878261Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Spartanburg
- GSK Investigational Site, Union
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 5 oct 2026 · NCT06961214Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
- GSK Investigational Site, Greenville
- GSK Investigational Site, Rock Hill
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 5 oct 2026 · NCT06959095A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Anderson
- Research Site, Charleston
- Research Site, Gaffney
- y 2 más
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 2 oct 2026 · NCT06283966A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, Rock Hill
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 3 sept 2026 · NCT06883305eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Greenville
- GSK Investigational Site, Rock Hill
ReclutandoFase 3
Edades de 40 a 75 · Todos los sexos · Actualizado el 28 jul 2026 · NCT07177339Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- Medical University of South Carolina (MUSC), Charleston
- McLeod Health, Florence
ReclutandoEstudio observacional
Edades de 50 en adelante · Todos los sexos · Actualizado el 5 ago 2025 · NCT06122077De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.